CHMP recommends Ryzodeg combination (Novo Nordisk) for treatment of Diabetes - 21-Oct-2012

On 18 October 2012, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ryzodeg, 100 units/mL, solution for injection from Novo Bordisk, intended for the treatment of diabetes mellitus. The active substances of Ryzodeg are insulin degludec and insulin aspart, a soluble insulin product consisting of the basal insulin degludec and the rapid-acting prandial insulin aspart. Insulin degludec and insulin aspart bind specifically to the human insulin receptor and results in the same pharmacological effects as human insulin.

Related News

Related Diabetes and Endocrinology Information

Related Diabetes and Endocrinology Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013